Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 3/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 4/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | LCLAT1 | Q6UWP7 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907486 | 0.92 | UGCG (0.54) | UGCGMETSCN9ALCLAT1 | |
| SCHEMBL29907352 | 0.86 | UGCG (0.67) | UGCGMETSCN9ALCLAT1 | |
| SCHEMBL24464270 | 0.84 | UGCG (0.62) | UGCGPTGESMETSCN9ALCLAT1 | |
| SCHEMBL29907412 | 0.84 | UGCG (0.62) | UGCGPTGESMETSCN9ALCLAT1 | |
| SCHEMBL29907369 | 0.84 | UGCG (0.62) | UGCGMETTP53SCN9ALCLAT1 | |
| SCHEMBL29907379 | 0.81 | UGCG (0.46) | UGCGPTGESSCN9A | |
| SCHEMBL29907392 | 0.80 | UGCG (0.79) | UGCGMETLCLAT1 | |
| SCHEMBL29907363 | 0.79 | SCN9A (0.46) | UGCGPTGESSCN9ALCLAT1 | |
| SCHEMBL29907372 | 0.78 | UGCG (0.63) | UGCGPTGESMETSCN9AIRAK4 | |
| SCHEMBL29907394 | 0.77 | UGCG (0.82) | UGCGMETLCLAT1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885GRM4 2346/4885PTGES 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.